Previous Close | 47.59 |
Open | 48.01 |
Bid | 46.59 x 900 |
Ask | 49.18 x 1400 |
Day's Range | 47.17 - 49.49 |
52 Week Range | 39.41 - 169.81 |
Volume | |
Avg. Volume | 571,700 |
Market Cap | 1.735B |
Beta (5Y Monthly) | 1.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.90 |
Earnings Date | Aug 03, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 70.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for NVRO
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions supporting the use of 10 kHz spinal cord stimulation (SCS) therapy for patients with chronic pain, including results from the SENZA Painful Diabetic Neuropathy (PDN) randomized controlled trial (RCT). Results were presented on Su
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, will be presented at the American Diabetes Association (ADA) 82nd Scientific Sessions to be held June 3-7, 2022 in New Orleans, LA. Nevro will also showcase the compan